Skip to content
2000
Volume 14, Issue 5
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/18715206113139990087
2014-06-01
2025-06-23
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/18715206113139990087
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test